TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsIndonesia begins clinical trials of homegrown COVID-19 candidate vaccine
Researchers recently began phase one clinical trials of a domestically produced COVID-19 candidate vaccine, a development that may bring the country closer to producing its first homegrown coronavirus jab.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A student receives a Sinovac COVID-19 vaccine dose at an elementary school in Banda Aceh on Jan. 18. (AFP/Chaideer Mahyuddin)
I
ndonesian researchers recently began phase one clinical trials of a domestically produced COVID-19 candidate vaccine, a development that may bring the country closer to producing its first homegrown coronavirus jab.
Airlangga University and partner PT Biotis Pharmaceuticals, which have developed the candidate vaccine under the Merah Putih initiative, claim that if the clinical trials are successful, the vaccine may be mass produced by July or August of this year.
The effort to produce a homegrown vaccine started in the early days of the pandemic as the country sought to achieve vaccine self-sufficiency amid an international scramble for scarce supplies.
The research team is part of a vaccine development consortium led by the Education, Culture, Research and Technology Ministry. Each constituent research team is developing a different COVID-19 candidate vaccine through various means, including the use of the inactivated virus, mRNA and DNA.
Early steps
On Feb. 7, the Food and Drug Monitoring Agency (BPOM) granted the Airlangga-Biotis research team approval to conduct phase one clinical trials on humans.
Some 90 volunteers received a first dose of the candidate vaccine on Feb. 9. They are set to receive the second dose 28 days later.
